Advertisement

Dysfunction of the Bowel/Constipation

  • Nagi B. Kumar
Chapter

Abstract

Constipation is commonly defined as having a bowel movement fewer than three times per week and characterized by stools that are hard, dry, small in size, and difficult and painful to eliminate. Individuals who are constipated experience straining, bloating, and the sensation of a full bowel.

Keywords

Fiber Intake Opioid Therapy Fecal Impaction Palliative Care Patient Cancer Patient Population 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Mahan KL, Escott-Stump S (2000) Krause’s food nutrition and diet therapy, 10th edn. W.B. Saunders Company, Philadelphia, pp 649–665Google Scholar
  2. 2.
    Longstreth GF (2006) Functional bowel disorders. Gastroenterology 130:1480–1491PubMedCrossRefGoogle Scholar
  3. 3.
    Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R (2009) The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med 10(1):35–42, Epub 2008 Aug 18PubMedCrossRefGoogle Scholar
  4. 4.
    Basson M (2007) Constipation. http://www.emedicine.com/med/topic2833.htm. Accessed March 2007
  5. 5.
    Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11S–18SPubMedCrossRefGoogle Scholar
  6. 6.
    Walsh TD (1990) Prevention of opioid side effects. J Pain Symptom Manage 5:362–367PubMedCrossRefGoogle Scholar
  7. 7.
    Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG (2010) Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 22(4):424–430, e96. Epub 2010 Jan 21PubMedCrossRefGoogle Scholar
  8. 8.
    Leppert W (2010) The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv Ther 27(10):714–730, Epub 2010 Aug 26PubMedCrossRefGoogle Scholar
  9. 9.
    Thomas JR, Cooney GA, Slatkin NE (2008) Palliative care and pain: new strategies for managing opioid bowel dysfunction. J Palliat Med 11(1):S1–S19, quiz S21–2PubMedCrossRefGoogle Scholar
  10. 10.
    Jamshed N, Lee ZE, Olden KW (2011) Diagnostic approach to chronic constipation in adults. Am Fam Physician 84(3):299–306PubMedGoogle Scholar
  11. 11.
    Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F (2010) Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci 14(12):1045–1050PubMedGoogle Scholar
  12. 12.
    Moore RA (2005) Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 7:R1046–R1051PubMedCrossRefGoogle Scholar
  13. 13.
    Kalso E (2004) Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 112:372–380PubMedCrossRefGoogle Scholar
  14. 14.
    Allan L et al (2001) Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322:1154–1158PubMedCrossRefGoogle Scholar
  15. 15.
    Meuser T (2001) Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. J Pain 93:247–257CrossRefGoogle Scholar
  16. 16.
    McMillan SC (2004) Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 11:3–9PubMedGoogle Scholar
  17. 17.
    Myotoku M, Nakanishi A, Kanematsu M, Sakaguchi N, Hashimoto N, Koyama F, Yamaguchi S, Ikeda K, Konishi H, Hirotani Y (2010) Reduction of opioid side effects by prophylactic measures of palliative care team may result in improved quality of life. J Palliat Med 13(4):401–406PubMedCrossRefGoogle Scholar
  18. 18.
    Panchal SJ, Müller-Schwefe P, Wurzelmann JI (2007) Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 61(7):1181–1187PubMedCrossRefGoogle Scholar
  19. 19.
    Klaschik E, Nauck F, Ostgathe C (2003) Constipation – modern laxative therapy. Support Care Cancer 11(11):679–685, Epub 2003 Sep 20PubMedCrossRefGoogle Scholar
  20. 20.
    Gibson RJ, Keefe DM (2006) Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 14(9):890–900, Epub 2006 Apr 8PubMedCrossRefGoogle Scholar
  21. 21.
    Walker LG, Eremin JM, Aloysius MM, Vassanasiri W, Walker MB, El-Sheemy M, Cowley G, Beer J, Samphao S, Wiseman J, Jibril JA, Valerio D, Clarke DJ, Kamal M, Thorpe GW, Baria K, Eremin O (2011) Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer 11:179PubMedCrossRefGoogle Scholar
  22. 22.
    Bennett M, Cresswell H (2003) Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, danthron dose and physical functioning. Palliat Med 17(5):418–422PubMedCrossRefGoogle Scholar
  23. 23.
    Longstreth GF, Yao JF (2010) Diseases and drugs that increase risk of acute large bowel ischemia. Clin Gastroenterol Hepatol 8(1):49–54, Epub 2009 Sep 16PubMedCrossRefGoogle Scholar
  24. 24.
    Herndon CM (2002) Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 22(2):240–250PubMedCrossRefGoogle Scholar
  25. 25.
    Raynov J, Danon S, Valerianova Z (2002) Control of acute emesis in repeated courses of moderately emetogenic chemotherapy. J BUON 7(1):57–60PubMedGoogle Scholar
  26. 26.
    Wirz S, Wittmann M, Schenk M, Schroeck A, Schaefer N, Mueller M, Standop J, Kloecker N, Nadstawek J (2009) Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 13(7):737–743, Epub 2008 Oct 31PubMedCrossRefGoogle Scholar
  27. 27.
    Holzer P (2007) Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 16:181–194PubMedCrossRefGoogle Scholar
  28. 28.
    Sternini C (2004) The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 16(Suppl 2):3–16PubMedCrossRefGoogle Scholar
  29. 29.
    Mehendale SR (2006) Opioid-induced gastrointestinal dysfunction. Dig Dis 24:105–112PubMedCrossRefGoogle Scholar
  30. 30.
    Sanger GJ (2004) The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modelling. Neurogastroenterol Motil 16(Suppl 2):38–45PubMedCrossRefGoogle Scholar
  31. 31.
    De Schepper HU (2004) Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 16:383–394PubMedCrossRefGoogle Scholar
  32. 32.
    Holzer P (2004) Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 361:192–195PubMedCrossRefGoogle Scholar
  33. 33.
    Shook JE (1987) Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther 243:492–500PubMedGoogle Scholar
  34. 34.
    De Luca A (1996) Insights into opioid action in the intestinal tract. Pharmacol Ther 69:103–115PubMedCrossRefGoogle Scholar
  35. 35.
    Clemens KE, Mikus G (2010) Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert Opin Pharmacother 11(2):297–310PubMedCrossRefGoogle Scholar
  36. 36.
    Pettit M (2005) Treatment of gastroesophageal reflux disease. Pharm World Sci 27:432–435PubMedCrossRefGoogle Scholar
  37. 37.
    Klepstad P (2000) Effects on cancer patients’ health-related quality of life after the start of morphine therapy. J Pain Symptom Manage 20:19–26PubMedCrossRefGoogle Scholar
  38. 38.
    Slappendel R (2006) Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 10:209–217PubMedCrossRefGoogle Scholar
  39. 39.
    Marquis P (2005) Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol 40:540–551PubMedCrossRefGoogle Scholar
  40. 40.
    Ueberall MA, Müller-Lissner S, Buschmann-Kramm C, Bosse B (2011) The bowel function index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 39(1):41–50PubMedGoogle Scholar
  41. 41.
    Rentz AM, Yu R, Müller-Lissner S, Leyendecker P (2009) Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 12(4):371–383PubMedCrossRefGoogle Scholar
  42. 42.
    Downing GM, Kuziemsky C, Lesperance M, Lau F, Syme A (2007) Development and reliability testing of the Victoria bowel performance scale (BPS). J Pain Symptom Manage 34(5):513–522, Epub 2007 Jul 30PubMedCrossRefGoogle Scholar
  43. 43.
    Hawley P, Barwich D, Kirk L (2011) Implementation of the Victoria bowel performance scale. J Pain Symptom Manage 42(6):946–953PubMedCrossRefGoogle Scholar
  44. 44.
    Belsey JD, Geraint M, Dixon TA (2010) Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract 64(7):944–955PubMedCrossRefGoogle Scholar
  45. 45.
    Lee-Robichaud H, Thomas K, Morgan J, Nelson RL (2010) Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev (7):CD007570Google Scholar
  46. 46.
    Chen CC, Su MY, Tung SY, Chang FY, Wong JM, Geraint M (2005) Evaluation of polyethylene glycol plus electrolytes in the treatment of severe constipation and faecal impaction in adults. Curr Med Res Opin 21(10):1595–1602PubMedCrossRefGoogle Scholar
  47. 47.
    van der Spoel JI, Oudemans-van Straaten HM, Kuiper MA, van Roon EN, Zandstra DF, van der Voort PH (2007) Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med 35(12):2726–2731PubMedCrossRefGoogle Scholar
  48. 48.
    Thomas J, Karver S, Cooney GA et al (2008) Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358(22):2332–2343PubMedCrossRefGoogle Scholar
  49. 49.
    Portenoy RK, Thomas J, Moehl Boatwright ML et al (2008) Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 35(5):458–468PubMedCrossRefGoogle Scholar
  50. 50.
    Meissner W, Leyendecker P, Mueller-Lissner S et al (2009) A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13(1):56–64PubMedCrossRefGoogle Scholar
  51. 51.
    Garnock-Jones KP, McKeage K (2010) Methylnaltrexone. Drugs 70(7):919–928. doi:10.2165/11204520-000000000-00000PubMedCrossRefGoogle Scholar
  52. 52.
    Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ (2009) Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage 38(5):683–690, Epub 2009 Aug 26PubMedCrossRefGoogle Scholar
  53. 53.
    Candy B, Jones L, Goodman ML, Drake R, Tookman A (2011) Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev (1):CD003448Google Scholar
  54. 54.
    Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64(7):777–794PubMedCrossRefGoogle Scholar
  55. 55.
    Fang ZW, Zhai SD (2010) A meta-analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting. Beijing Da Xue Xue Bao 42(6):756–763PubMedGoogle Scholar
  56. 56.
    Wood JD (2004) Function of opioids in the enteric nervous system. Neurogastroenterol Motil 16(Suppl 2):17–28PubMedCrossRefGoogle Scholar
  57. 57.
    Camilleri M (2005) Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 17(2):157–165PubMedCrossRefGoogle Scholar
  58. 58.
    Ebert EC (2010) The thyroid and the gut. J Clin Gastroenterol 44(6):402–406PubMedGoogle Scholar
  59. 59.
    Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT (1993) The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 306(6890):1440–1444PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.University of South FloridaTampaUSA

Personalised recommendations